Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 (platelet factor-4 variant) are mediated by CXCR3

Blood

Volumn 117, Issue 2, 2011, Pages 480-488

  Struyf, Sofie ^a   Salogni, Laura ^b   Burdick, Marie D ^c   Vandercappellen, Jo ^a   Gouwy, Mieke ^a   Noppen, Sam ^a   Proost, Paul ^a   Opdenakker, Ghislain ^a   Parmentier, Marc ^d   Gerard, Craig ^e   Sozzani, Silvano ^b   Strieter, Robert M ^c   Van Damme, Jo ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY OF VIRGINIA   (United States)

^d UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^e BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CXCL4L1; CHEMOKINE RECEPTOR CXCR3; GLYCOSAMINOGLYCAN; THROMBOCYTE FACTOR 4; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL MIGRATION; CHEMOTAXIS; DENDRITIC CELL; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IN VIVO STUDY; NATURAL KILLER CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 78751562091     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-11-253591     Document Type: Article

References (43)

1. Strieter RM, Burdick MD, Gomperts BN, Belperio JA, Keane MP. CXC chemokines in angiogenesis. Cytokine Growth Factor Rev. 2005;16(6):593-609.
2. Vandercappellen J, Van Damme J, Struyf S. The role of CXC chemokines and their receptors in cancer. Cancer Lett. 2008;267(2):226-244.
3. Maione TE, Gray GS, Petro J, et al. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science. 1990;247(4938):77-79. (Pubitemid 20059941)
4. Green CJ, Charles RS, Edwards BF, Johnson PH. Identification and characterization of PF4varl, a human gene variant of platelet factor 4. Mol Cell Biol. 1989;9(4):1445-1451. (Pubitemid 19095184)
5. Eisman R, Surrey S, Ramachandran B, Schwartz E, Poncz M. Structural and functional comparison of the genes for human platelet factor 4 and PF4alt. Blood. 1990;76(2):336-344.
6. Struyf S, Burdick MD, Proost P, Van Damme J, Strieter RM. Platelets release CXCL4L1, a nonallelic variant of the chemokine platelet factor-4/CXCL4 and potent inhibitor of angiogenesis. Circ Res. 2004;95(9):855-857.
7. Vandercappellen J, Noppen S, Verbeke H, et al. Stimulation of angiostatic platelet factor-4 variant (CXCL4L1/PF-4var) versus inhibition of angiogenic granulocyte chemotactic protein-2 (CXCL6/GCP-2) in normal and tumoral mesenchymal cells. J Leukoc Biol. 2007;82(6):1519-1530.
8. Lasagni L, Grepin R, Mazzinghi B, et al. PF-4/CXCL4 and CXCL4L1 exhibit distinct subcellular localization and a differentially regulated mechanism of secretion. Blood. 2007;109(10):4127-4134.
9. Struyf S, Burdick MD, Peeters E, et al. Platelet factor-4 variant chemokine CXCL4L1 inhibits melanoma and lung carcinoma growth and metastasis by preventing angiogenesis. Cancer Res. 2007;67(12):5940-5948. (Pubitemid 46985030)
10. Proost P, Mortier A, Loos T, et al. Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration. Blood. 2007;110(1):37-44.
11. Addison CL, Belperio JA, Burdick MD, Strieter RM. Overexpression of the duffy antigen receptor for chemokines (DARC) by NSCLC tumor cells results in increased tumor necrosis. BMC Cancer. 2004;4:28-43.
12. Sharma S, Yang SC, Hillinger S, et al. SLC/CCL21-mediated anti-tumor responses require IFNγ, MIG/CXCL9 and IP-10/CXCL10. Mol Cancer. 2003;2:22-28.
13. Hancock WW, Lu B, Gao W, et al. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med. 2000;192(10):1515-1520.
14. Proost P, Schutyser E, Menten P, et al. Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. Blood. 2001;98(13):3554-3561.
15. Salogni L, Musso T, Bosisio D, et al. Activin A induces dendritic cell migration through the polarized release of CXC chemokine ligands 12 and 14. Blood. 2009;113(23):5848-5856.
16. Struyf S, Noppen S, Loos T, et al. Citrullination of CXCL12 differentially reduces CXCR4 and CXCR7 binding, with loss of inflammatory and anti-HIV-1 activity via CXCR4. J Immunol. 2009;182(1):666-674.
17. Lasagni L, Francalanci M, Annunziato F, et al. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med. 2003;197(11):1537-1549.
18. Hensbergen PJ, Wijnands PG, Schreurs MW, et al. The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in vivo involving attraction of CD8+ T lymphocytes but not inhibition of angiogenesis. J Immunother. 2005;28(4):343-351.
19. Fleischer J, Grage-Griebenow E, Kasper B, et al. Platelet factor 4 inhibits proliferation and cytokine release of activated human T cells. J Immunol. 2002;169(2):770-777.
20. Mueller A, Meiser A, McDonagh EM et al. CXCL4-induced migration of activated T lymphocytes is mediated by the chemokine receptor CXCR3. J Leukoc Biol. 2008;83(4):875-882.
21. Pervushina O, Scheuerer B, Reiling N, et al. Platelet factor 4/CXCL4 induces phagocytosis and the generation of reactive oxygen metabolites in mononuclear phagocytes independently of Gi protein activation or intracellular calcium transients. J Immunol. 2004;173(3):2060-2067. (Pubitemid 38971643)
22. Petersen F, Brandt E, Lindahl U, Spillmann D. Characterization of a neutrophil cell surface glycosaminoglycan that mediates binding of platelet factor 4. J Biol Chem. 1999;274(18):12376-12382.
23. Datta D, Contreras AG, Grimm M, et al. Calcineurin inhibitors modulate CXCR3 splice variant expression and mediate renal cancer progression. J Am Soc Nephrol. 2008;19(12):2437-2446.
24. Burns JM, Summers BC, Wang Y, et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med. 2006;203(9):2201-2213.
25. Vicari AP, Treilleux I, Lebecque S. Regulation of the trafficking of tumour-infiltrating dendritic cells by chemokines. Semin Cancer Biol. 2004;14(3):161-169.
26. Colvin RA, Campanella GS, Sun J, Luster AD. Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function. J Biol Chem. 2004;279(29):30219-30227.
27. Xanthou G, Williams TJ, Pease JE. Molecular characterization of the chemokine receptor CXCR3: evidence for the involvement of distinct extracellular domains in a multi-step model of ligand binding and receptor activation. Eur J Immunol. 2003;33(10):2927-2936. (Pubitemid 37337159)
28. Preston RJ, Tran S, Johnson JA, et al. Platelet factor 4 impairs the anticoagulant activity of activated protein C. J Biol Chem. 2009;284(9):5869- 5875.
29. Petersen F, Bock L, Flad HD, Brandt E. Platelet factor 4-induced neutrophil-endothelial cell interaction: involvement of mechanisms and functional consequences different from those elicited by interleukin-8. Blood. 1999;94(12):4020-4028.
30. Perollet C, Han ZC, Savona C, Caen JP, Bikfalvi A. Platelet factor 4 modulates fibroblast growth factor 2 (FGF-2) activity and inhibits FGF-2 dimerization. Blood. 1998;91(9):3289-3299. (Pubitemid 28193879)
31. Nesmelova IV, Sham Y, Gao J, Mayo KH. CXC and CC chemokines form mixed heterodimers: association free energies from molecular dynamics simulations and experimental correlations. J Biol Chem. 2008;283(35):24155-24166.
32. von Hundelshausen P, Koenen RR, Sack M et al. Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium. Blood. 2005;105(3):924-930.
33. Ehlert JE, Addison CA, Burdick MD, Kunkel SL, Strieter RM. Identification and partial characterization of a variant of human CXCR3 generated by posttranscriptional exon skipping. J Immunol. 2004;173(10):6234-6240.
34. Thompson BD, Jin Y, Wu KH, et al. Inhibition of G α i2 activation by G α i3 in CXCR3-mediated signaling. J Biol Chem. 2007;282(13):9547- 9555.
35. Sozzani S. Dendritic cell trafficking: more than just chemokines. Cytokine Growth Factor Rev. 2005;16(6):581-592.
36. Howard OM, Dong HF, Su SB, et al. Autoantigens signal through chemokine receptors: uveitis antigens induce CXCR3- and CXCR5-expressing lymphocytes and immature dendritic cells to migrate. Blood. 2005;105(11):4207-4214.
37. Inngjerdingen M, Damaj B, Maghazachi AA. Expression and regulation of chemokine receptors in human natural killer cells. Blood. 2001;97(2):367-375.
38. Qin S, Rottman JB, Myers P, et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest. 1998;101(4):746-754.
39. Xia CQ, Kao KJ. Effect of CXC chemokine platelet factor 4 on differentiation and function of monocyte-derived dendritic cells. Int Immunol. 2003;15(8):1007-1015.
40. Marti F, Bertran E, Llucia M, et al. Platelet factor 4 induces human natural killer cells to synthesize and release interleukin-8. J Leukoc Biol. 2002;72(3):590-597.
41. Luster AD, Greenberg SM, Leder P. The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. J Exp Med. 1995;182(1):219-231.
42. St Charles R, Walz DA, Edwards BF. The three-dimensional structure of bovine platelet factor 4 at 3.0-A resolution. J Biol Chem. 1989;264(4):2092- 2099.
43. Johnson Z, Proudfoot AE, Handel TM. Interaction of chemokines and glycosaminoglycans: a new twist in the regulation of chemokine function with opportunities for therapeutic intervention. Cytokine Growth Factor Rev. 2005;16(6):625-636.